Preview

Пульмонология

Расширенный поиск

Рекомендации Франкоязычного общества пульмонологии по ведению злокачественной мезотелиомы плевры

https://doi.org/10.18093/0869-0189-2007-0-6-12-22

Полный текст:

Об авторе

А. Шеперель
Институт Пастера; Отделение легочной и торакальной онкологии Университетского госпиталя
Франция
Париж
Лилль


Список литературы

1. Robinson B.W., Musk A.W., Lake R.A. Malignant mesothelioma. Lancet 2005; 366: 397–408.

2. Chang K.C., Leung C.C. Malignant mesothelioma: a minor issue about gender ratio and a major issue about regulatory policy. Respir. Med. 2006; 100: 1123–1124.

3. Ordonez N.G. The immunohistochemical diagnosis of mesothelioma: a comparative study of epithelioid mesothelioma and lung adenocarcinoma. Am. J. Surg. Pathol. 2003; 27: 1031–1051.

4. Pass H.I., Vogelzang N., Hahn S., Carbone M. Malignant pleural mesothelioma. Curr. Probl. Cancer. 2004; 28: 93–174.

5. West S.D., Foord T., Davies R.J. Needle-track metastases and prophylactic radiotherapy for mesothelioma. Respir. Med. 2006; 100: 1037–1040.

6. Societe de Pneumologie de Langue Francaise. The French language Society of Pneumology guidelines on the pleural mesothelioma. Rev. Mal. Respir. 2006; 23 (suppl. 3): 6S806S92. (Copyright SPLF, Paris 2006, all rights reserved).

7. Travis W.D., Brambilla E., Mыller2Hermelink H.K., Harris C. Tumours of the lung, pleura, thymus and heart. Lyon: WHO, IARC Press; 2004.

8. Vogelzang N.J., Rusthoven J.J., Symanowski J. et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J. Clin. Oncol. 2003; 21: 2636–2644.

9. van Meerbeeck J.P., Gaafar R., Manegold C. et al. European Organisation for Research and Treatment of Cancer Lung Cancer Group; National Cancer Institute of Canada. Randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an intergroup study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Institute of Canada. J. Clin. Oncol. 2005; 23: 6881–6889.

10. Bottomley A., Gaafar R., Manegold C. et al. EORTC LungCancer Group; National Cancer Institute, Canada. Shortterm treatment-related symptoms and quality of life: results from an international randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an EORTC Lung-Cancer Group and National Cancer Institute, Canada, Intergroup Study. J. Clin. Oncol. 2006; 24: 1435–1442.

11. O’Brien M.E., Watkins D., Ryan C., Priest K., Corbishley C., Norton A., et al. A randomised trial in malignant mesothelioma (M) of early (E) versus delayed (D) chemotherapy in symptomatically stable patients: the MED trial. Ann. Oncol. 2006; 17: 270–275.


Рецензия

Для цитирования:


Шеперель А. Рекомендации Франкоязычного общества пульмонологии по ведению злокачественной мезотелиомы плевры. Пульмонология. 2007;(6):12-22. https://doi.org/10.18093/0869-0189-2007-0-6-12-22

For citation:


Scherpereel A. Guidelines of the French Speaking Society for Chest Medicine for management of malignant pleural mesothelioma. PULMONOLOGIYA. 2007;(6):12-22. (In Russ.) https://doi.org/10.18093/0869-0189-2007-0-6-12-22

Просмотров: 109


ISSN 0869-0189 (Print)
ISSN 2541-9617 (Online)